[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Views 509
Citations 0
Health Agencies Update
July 25, 2017

Chikungunya Vaccine Trials Begin

JAMA. 2017;318(4):322. doi:10.1001/jama.2017.8753

A phase 1 and 2 clinical trial of an experimental vaccine against the viral disease chikungunya has begun enrolling a planned 180 healthy adult volunteers aged 18 to 45 years with funding by the National Institute of Allergy and Infectious Diseases (NIAID). The vaccine, known as MV-CHIKV, is a recombinant live-attenuated measles vaccine virus expressing chikungunya proteins that induce antibody production.